Olli Dufva

2.2k total citations
31 papers, 719 citations indexed

About

Olli Dufva is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Olli Dufva has authored 31 papers receiving a total of 719 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 15 papers in Immunology and 13 papers in Oncology. Recurrent topics in Olli Dufva's work include Immune Cell Function and Interaction (12 papers), Acute Myeloid Leukemia Research (11 papers) and CAR-T cell therapy research (11 papers). Olli Dufva is often cited by papers focused on Immune Cell Function and Interaction (12 papers), Acute Myeloid Leukemia Research (11 papers) and CAR-T cell therapy research (11 papers). Olli Dufva collaborates with scholars based in Finland, United States and Norway. Olli Dufva's co-authors include Satu Mustjoki, Kimmo Porkka, Oscar Brück, Petri Pölönen, Tero Aittokallio, Caroline A. Heckman, Aleksandr Ianevski, Matti Kankainen, Helena Hohtari and Pilvi Maliniemi and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Olli Dufva

28 papers receiving 716 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olli Dufva Finland 13 321 303 247 241 130 31 719
Mingqing Zhu China 11 439 1.4× 246 0.8× 380 1.5× 278 1.2× 66 0.5× 53 809
Fei Fei United States 14 241 0.8× 227 0.7× 215 0.9× 229 1.0× 113 0.9× 46 654
Nadja Zaborsky Austria 18 336 1.0× 283 0.9× 386 1.6× 102 0.4× 256 2.0× 49 945
S. M. Luger United States 8 372 1.2× 407 1.3× 274 1.1× 492 2.0× 141 1.1× 14 949
Morten Orebo Holmström Denmark 15 289 0.9× 202 0.7× 301 1.2× 239 1.0× 282 2.2× 42 740
Chelsea J. Gudgeon United States 11 308 1.0× 220 0.7× 177 0.7× 206 0.9× 32 0.2× 16 532
August H. Westra Netherlands 9 211 0.7× 281 0.9× 161 0.7× 545 2.3× 137 1.1× 11 774
Francesco Lanza Italy 15 205 0.6× 292 1.0× 159 0.6× 116 0.5× 41 0.3× 31 809
Cecilia Carpio Spain 15 388 1.2× 214 0.7× 197 0.8× 110 0.5× 200 1.5× 55 774
Xingwei Sui Japan 13 428 1.3× 329 1.1× 336 1.4× 331 1.4× 200 1.5× 18 933

Countries citing papers authored by Olli Dufva

Since Specialization
Citations

This map shows the geographic impact of Olli Dufva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olli Dufva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olli Dufva more than expected).

Fields of papers citing papers by Olli Dufva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olli Dufva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olli Dufva. The network helps show where Olli Dufva may publish in the future.

Co-authorship network of co-authors of Olli Dufva

This figure shows the co-authorship network connecting the top 25 collaborators of Olli Dufva. A scholar is included among the top collaborators of Olli Dufva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olli Dufva. Olli Dufva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jokinen, Emmi, Essi Laajala, Shady Adnan Awad, et al.. (2025). High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia. Blood. 145(15). 1670–1686. 2 indexed citations
2.
Meriranta, Leo, Kanutte Huse, Xiaonan Liu, et al.. (2024). Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma. Blood Cancer Discovery. 5(5). 331–352. 3 indexed citations
3.
Pfefferle, Aline, Jodie P. Goodridge, Ebba Sohlberg, et al.. (2024). Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping. Nature Immunology. 25(8). 1445–1459. 28 indexed citations
4.
Dai, Jun, Shuyu Zheng, Matías Marín Falco, et al.. (2024). Tracing back primed resistance in cancer via sister cells. Nature Communications. 15(1). 1158–1158. 7 indexed citations
5.
Awad, Shady Adnan, Olli Dufva, Jay Klievink, et al.. (2024). Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia. Cell Reports Medicine. 5(5). 101521–101521. 9 indexed citations
6.
Huuhtanen, Jani, Katriina Peltola, Tapio Lönnberg, et al.. (2023). Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma. Journal of Clinical Investigation. 133(6). 60 indexed citations
7.
Huuhtanen, Jani, Shady Adnan Awad, Olli Dufva, et al.. (2023). Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia. 38(1). 109–125. 17 indexed citations
8.
Dufva, Olli, Emmi Jokinen, Hanna Lähteenmäki, et al.. (2023). Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells. Blood. 142(Supplement 1). 66–66.
9.
Jokinen, Emmi, Essi Laajala, Aleksandr Ianevski, et al.. (2023). High-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers. Blood. 142(Supplement 1). 3634–3634.
10.
Huuhtanen, Jani, Oscar Brück, Karita Peltonen, et al.. (2021). Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS. Blood. 138(Supplement 1). 801–801. 1 indexed citations
11.
Gandolfi, Sara, Olli Dufva, Jani Huuhtanen, et al.. (2021). Functional Genomic Landscape of Natural Killer Cell Evasion in Multiple Myeloma. Blood. 138(Supplement 1). 732–732. 2 indexed citations
12.
Awad, Shady Adnan, Olli Dufva, Aleksandr Ianevski, et al.. (2020). RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 35(4). 1087–1099. 35 indexed citations
13.
Dufva, Olli, Pilvi Maliniemi, Aleksandr Ianevski, et al.. (2019). Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 135(9). 597–609. 157 indexed citations
14.
Kuusanmäki, Heikki, Aino‐Maija Leppä, Petri Pölönen, et al.. (2019). Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 105(3). 708–720. 106 indexed citations
15.
Brück, Oscar, Sami Blom, Olli Dufva, et al.. (2018). Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia. 32(7). 1643–1656. 69 indexed citations
16.
Awad, Shady Adnan, Matti Kankainen, Olli Dufva, et al.. (2018). RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities. Blood. 132(Supplement 1). 4257–4257. 5 indexed citations
17.
Brück, Oscar, Mikko Keränen, Olli Dufva, Anna Kreutzman, & Satu Mustjoki. (2018). T cells and cancer - why do the killers become exhausted?. PubMed. 132(21). 1984–92. 1 indexed citations
18.
Dufva, Olli, Petri Pölönen, Mikko Keränen, et al.. (2016). Pan-Hematopoietic Cancer Gene Expression Analysis Identifies Immunologically Active Acute Myeloid Leukemia Subtypes. Blood. 128(22). 1725–1725. 1 indexed citations
19.
Kämpjärvi, Kati, Tiina M. Järvinen, Tuomas Heikkinen, et al.. (2014). Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget. 6(3). 1884–1888. 35 indexed citations
20.
Wiener, Zoltán, Arja M. Band, Pauliina Kallio, et al.. (2014). Prox1 Promotes Expansion of the Colorectal Cancer Stem Cell Population to Fuel Tumor Growth and Ischemia Resistance. Cell Reports. 8(6). 1943–1956. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mingqing Zhu Breakdown of academic impact, for papers by Fei Fei Breakdown of academic impact, for papers by Nadja Zaborsky Breakdown of academic impact, for papers by S. M. Luger Breakdown of academic impact, for papers by Morten Orebo Holmström Breakdown of academic impact, for papers by Chelsea J. Gudgeon Breakdown of academic impact, for papers by August H. Westra Breakdown of academic impact, for papers by Francesco Lanza Breakdown of academic impact, for papers by Cecilia Carpio Breakdown of academic impact, for papers by Xingwei Sui
Rankless by CCL
2026